Lululemon Athletica Aims To Double Revenue By 2026

Lululemon Athletica Inc. (LULU) said that it aims to double its 2021 revenue of $6.25 billion to $12.5 billion by 2026.

The company expects to double the size of its men's revenues in 2021 by 2026, along with ongoing expansion in its women's and accessories businesses.

The company said it is on track to successfully achieve 2023 revenue and earnings growth targets ahead of schedule.

The company's Power of Three ×2 growth strategy include total net revenue CAGR of 15% between 2021 and 2026; modest operating expansion annually; earning per share growth to outpace revenue growth; annual square footage growth in the low double digits.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT